Brian Park, PharmD

Drug Information Specialist https://www.endocrinologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Diabetes

Insulin Product Samples Recalled Due to Improper Storage Temperature Conditions

Brian Park, PharmD

May 13, 2021

The product samples are being recalled because they were stored at temperatures below storage requirements.

Thyroid

Certain Lots of NP Thyroid Recalled Due to Subpotent Tablets

Brian Park, PharmD

May 6, 2021

Acella Pharmaceuticals announced the voluntary recall of several lots of NP Thyroid (thyroid tablets) 15mg, 30mg, 60mg, 90mg, and 120mg due to subpotency.

We review the role of a new class of agents in improving glycemic control and reducing diabetes-related vascular disease.

Type 1 Diabetes

Oral Glucokinase Activator Gets Breakthrough Tx Status for Type 1 Diabetes

Brian Park, PharmD

May 4, 2021

TTP399 is an investigational oral, hepatoselective glucokinase activator.

Cardiovascular and Metabolic Disorders

Alirocumab Approved for Homozygous Familial Hypercholesterolemia

Brian Park, PharmD

April 8, 2021

The approval was based on data from the phase 3 ODYSSEY HoFH trial, which evaluated Praluent in 69 adults with HoFH who were on other LDL-C-lowering therapies.

General Endocrinology

FDA Launches Adverse Event Reporting Dashboard for Authorized COVID-19 Therapeutics

Brian Park, PharmD

April 1, 2021

Data will be reported to the FDA by the pharmaceutical industry, health care providers, and consumers.

Androgen and Reproductive Disorders

Fezolinetant Reduces Vasomotor Symptoms Associated With Menopause

Brian Park, PharmD

March 5, 2021

Fezolinetant is designed to reduce the frequency and severity of VMS associated with menopause by inhibiting neurokinin B binding on the kisspeptin/neurokinin/dynorphin neuron.

Thyroid

Cabozantinib Gets Breakthrough Tx Status for Differentiated Thyroid Cancer

Brian Park, PharmD

March 2, 2021

The designation is supported by data from the randomized, double-blind, placebo-controlled phase 3 COSMIC-311 study.

Thyroid

Thyquidity Oral Solution Now Available for Hypothyroidism

Brian Park, PharmD

February 26, 2021

Thyquidity (levothyroxine sodium) oral solution is indicated for the treatment of hypothyroidism and pituitary thyrotropin suppression.

Androgen and Reproductive Disorders

Fezolinetant Reduces Vasomotor Symptoms Associated With Menopause

Brian Park, PharmD

February 25, 2021

Fezolinetant is designed to reduce the frequency and severity of VMS associated with menopause by inhibiting neurokinin B binding on the kisspeptin/neurokinin/dynorphin neuron.

Practice Management

Digital Health App Tracks Pain Progress With Neurostimulation Therapy

Brian Park, PharmD

February 4, 2021

Patients will be able to share information collected in the app with health care providers to provide a comprehensive assessment of the SCS or DRG therapy.

Next post in Practice Management